Lexaria Bioscience Corp (LEXX): It would seem to me they are more intere...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Lexaria Bioscience Corp (LEXX)

Reply Private New

Keep Last Read

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	30
Posts	2386
Boards Moderated	0
Alias Born	04/10/2014

Re: MasterBidder post# 21543

Wednesday, 04/18/2018 2:25:18 PM

Wednesday, April 18, 2018 2:25:18 PM

It would seem to me they are more interested in becoming a successful Bio tech company than making money, I’m starting to wonder if they had a buy out offer would they take it? Or just push for a licensing deal and lose both. Profit does not seem to be their motive,either that or they are totally inept.

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent LEXX News

Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/06/2024 11:00:40 AM
Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 07:28:18 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:30:59 PM
Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/16/2024 08:47:26 PM
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:20:50 PM
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:00:12 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 06:51:13 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 07:12:07 PM
Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/24/2024 06:33:08 PM
Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/18/2024 07:38:18 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/12/2024 10:11:16 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream • GlobeNewswire Inc. • 01/11/2024 01:30:00 PM
Beyond Diabetes, a Blockbuster Horizon Beckons • InvestorsHub NewsWire • 01/10/2024 01:45:00 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs • InvestorsHub NewsWire • 01/08/2024 01:45:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 10:07:45 PM
Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 11/30/2023 09:14:31 PM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/20/2023 10:16:25 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 05:13:38 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2023 05:45:34 PM
Get Ready for Next Generation of Diabetes, Weight-Management Drugs • InvestorsHub NewsWire • 11/01/2023 12:45:00 PM

More LEXX News

InvestorsHub NewsWire

Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow